BCL2L11 and glioma: The resistance of glioma tumor cells to gefitinib has been associated to a loss of expression of PTEN [215] and the phosphorylation (degradation) of the pro-apoptotic protein Bim by ERK, activated via the urokinase plasminogen activator (uPA)/uPAR/MEK [224].